期刊文献+

P物质及其受体NK-1R在肿瘤中的研究进展 被引量:2

Research progress of substance P and its receptor NK-1R in tumors
下载PDF
导出
摘要 P物质是一种进化保守的小分子活性肽,主要由神经元分泌,属于速激肽家族。P物质主要与G蛋白偶联受体家族的神经激肽-1受体结合,从而发挥多种生物学效应,包括痛觉传递、炎症及免疫调节等。目前研究发现,P物质及其受体神经激肽-1R(NK-1R)参与了肿瘤的演进过程,本文综述了P物质及其受体NK-1R与肿瘤最新的相关研究进展,揭示P物质及其受体NK-1R在恶性肿瘤发生、发展过程中的意义。 The substance P is an evolutionarily conserved small molecule active peptide which mainly secreted by neurons and belongs to the tachykinin family.The substance P mainly binds to the neurokinin 1 receptors which belong to the G protein coupled receptor family to exert a variety of biological effects,including pain transmission,inflammation and immune regulation and so on.The current studies have found that the substance P and its receptor NK-1R are involved in the evolution process of tumors.This paper reviews the latest related research progress of substance P and its receptor NK-1R with tumors and reveals the significance of substance P and its receptor NK-1R in the occurrence and development process of malignant tumors.
作者 张渝 杨昆(综述) 黄江菊(审校) ZHANG Yu;YANG Kun;HUANG Jiangju(Department of Otolaryngology Head and Neck Surgery,First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处 《重庆医学》 CAS 2020年第24期4194-4198,共5页 Chongqing medicine
基金 国家自然科学基金项目(81700895)。
关键词 P物质 神经激肽-1R 肿瘤 substance P neurokinin-1 receptor tumor
  • 相关文献

参考文献2

二级参考文献17

  • 1王秀萍,郭政.P物质与呼吸道炎症[J].国外医学(麻醉学与复苏分册),2005,26(6):321-324. 被引量:16
  • 2Rebecca Siegel,Deepa Naishadham,Ahmedin Jemal.Cancer statistics, 2013[J]. CA: A Cancer Journal for Clinicians . 2013 (1)
  • 3Kate M. Lewis,Elizabeth Harford-Wright,Robert Vink,Alan J. Nimmo,Mounir N. Ghabriel.Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood–brain barrier during extravasation and brain invasion[J].Clinical & Experimental Metastasis.2013(1)
  • 4Miguel Mu?oz,Ana González-Ortega,Marisa Rosso,María José Robles-Frias,Andres Carranza,Manuel Vicente Salinas-Martín,Rafael Cove?as.The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists[J].Peptides.2012(2)
  • 5David Borsook,Jaymin Upadhyay,Michael Klimas,Adam J. Schwarz,Alexandre Coimbra,Richard Baumgartner,Edward George,William Z. Potter,Thomas Large,David Bleakman,Jeffrey Evelhoch,Smriti Iyengar,Lino Becerra,Richard J. Hargreaves.Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain[J].Drug Discovery Today (-).2012(17-18)
  • 6Muneer Abidi,Nishant Tageja,Lois Ayash,Judith Abrams,Voravit Ratanatharathorn,Zaid Al-Kadhimi,Lawrence Lum,Simon Cronin,Marie Ventimiglia,Joseph Uberti.Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial[J].Supportive Care in Cancer.2012(10)
  • 7Steven D.Douglas,Susan E.Leeman.Neurokinin‐1 receptor: functional significance in the immune system in reference to selected infections and inflammation[J].Annals of the New York Academy of Sciences.2011(1)
  • 8Miguel Mu?oz,Ana González-Ortega,Rafael Cove?as.The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines[J].Investigational New Drugs.2012(2)
  • 9Miguel Mu?oz,Marisa Rosso,Ana González,Javier Saenz,Rafael Cove?as.The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile[J].Peptides.2010(9)
  • 10Miguel Mu?oz,Marisa Rosso.The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug[J].Investigational New Drugs.2010(2)

共引文献5

同被引文献11

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部